Abstract:Myasthenia gravis (MG) is a chronic and progressive neuromuscular disease where autoantibodies target essential proteins such as the nicotinic acetylcholine receptor (nAChR) at the neuromuscular junction (NMJ) causing muscle fatigue and weakness. Autoantibodies directed against nAChRs are proposed to work by three main pathological mechanisms of receptor disruption: blocking, receptor internalization, and downregulation. Current in vivo models using experimental autoimmune animal models fail to recapitulate the disease pathology and are limited in clinical translatability due to disproportionate disease severity and high animal death rates. The development of a highly sensitive antibody assay that mimics human disease pathology is desirable for clinical advancement and therapeutic development. To address this lack of relevant models, an NMJ platform derived from human iPSC differentiated motoneurons and primary skeletal muscle was used to investigate the ability of an anti-nAChR antibody to induce clinically relevant MG pathology in the serum-free, spatially organized, functionally mature NMJ platform. Treatment of the NMJ model with the anti-nAChR antibody revealed decreasing NMJ stability as measured by the number of NMJs before and after the synchrony stimulation protocol. This decrease in NMJ stability was dose-dependent over a concentration range of 0.01-20 μg/mL. Immunocytochemical (ICC) analysis was used to distinguish between pathological mechanisms of antibody-mediated receptor disruption including blocking, receptor internalization and downregulation. Antibody treatment also activated the complement cascade as indicated by complement protein 3 deposition near the nAChRs. Additionally, complement cascade activation significantly altered other readouts of NMJ function including the NMJ fidelity parameter as measured by the number of muscle contractions missed in response to increasing motoneuron stimulation frequencies. This synchrony readout mimics the clinical phenotype of neurological blocking that results in failure of muscle contractions despite motoneuron stimulations. Taken together, these data indicate the establishment of a relevant disease model of MG that mimics reduction of functional nAChRs at the NMJ, decreased NMJ stability, complement activation and blocking of neuromuscular transmission. This system is the first functional human in vitro model of MG to be used to simulate three potential disease mechanisms as well as to establish a preclinical platform for evaluation of disease modifying treatments (etiology).

Institution of Model of Myasthenia Gravis in Transgenic Mice

Establishment of a Mouse Model of Experimental Autoimmune Myasthenia Gravis

Pathogenesis of Myasthenia Gravis in Transgenic Mouse Induced with Torpedo Acetylcholine Receptor

Development of an improved animal model of experimental autoimmune myositis.

Establishment of Animal Models of Experimental Autoimmune Myositis

Experimental autoimmune myasthenia gravis in mice expressing human immunoglobulin loci

Establishment of the animal model of experimental autoimmune myositis

Improved methodology to obtain large quantities of correctly folded recombinant N-terminal extracellular domain of the human muscle acetylcholine receptor for inducing experimental autoimmune myasthenia gravis in rats

PATHOGENICITY AND SEQUENCE ANALYSIS OF A MOUSE MONOCLONAL ANTIBODY AGAINST HUMAN ACETYLCHOLINE RECEPTOR IN MYASTHENIA GRAVIS

A new mouse model of autoimmune ocular myasthenia gravis.

Mice with IFN-gamma Receptor Deficiency Are Less Susceptible to Experimental Autoimmune Myasthenia Gravis.

Artificial Construction of Human Pathogenic Autoantibody in Myasthenia Gravis

Model of Passive Transferred Experimental Myasthenia Gravis Inducing on Sprague-Dawley Rats

Ocular Myasthenia Gravis Induced By Human Acetylcholine Receptor Epsilon Subunit Immunization In Hla Dr3 Transgenic Mice

Experimental autoimmune myositis model induced by pure myosin of rabbit

Suppression of Experimental Autoimmune Myasthenia Gravis by Nasal Administration of Acetylcholine Receptor

Construction of a myasthenia gravis model by immunizing mice with gene vaccine pcDNA-AChR_(α211)

The Effect of CD3-specific Monoclonal Antibody on Treating Experimental Autoimmune Myasthenia Gravis.

A novel model of central nervous system involvement in myasthenia gravis

Study on the Effect of Huangqi-Gegen Decoction and Peiyuan-Guben Powder on Autoimmune Myasthenia Gravis Rats

A Functional Human-on-a-Chip Autoimmune Disease Model of Myasthenia Gravis for Development of Therapeutics